Notícias

Amgen’s second quarter results reflected broad-based portfolio momentum, with management crediting double-digit growth in key products like Repatha, EVENITY, and TEZSPIRE for the company’s outperformance versus Wall Street estimates. CEO Robert Bradway highlighted that 22 products achieved double-digit sales growth, and 17 products annualized over $1 billion in sales, noting, “Our strong results were driven by the breadth and depth of our portfolio and once again demonstrate our ability to grow

BeOne Medicines Ltd (ONC) delivers robust Q2 2026 results with record BRUKINSA sales, raises full-year guidance, and advances a promising oncology pipeline.

Management raised its full-year forecast, but the market seems to be asking for more than a higher target.

Revenue surged 10% as six growth drivers now fuel 70% of product sales.

Mineralys Therapeutics (NASDAQ:MLYS) said it is continuing commercial-launch preparations for lorundrostat ahead of its December 22 Prescription Drug User Fee Act target date, while reporting a wider second-quarter loss driven largely by a $200 million upfront payment related to its amended agreemen

Three household names are days away from their ex-dividend dates, and missing the cutoff by even one session means that specific cash payment goes to someone else. The clock is running on MSFT, AMGN, and MAR.

BioCryst just turned profitable, its HAE drug Orladeyo is minting cash, and a rival's blockbuster acquisition just put the whole rare-disease sector in play. So which pharma giant has the most to lose by letting someone else snap it up first?

Eli Lilly's growth is huge, but on its latest call, analysts tested whether the next chapter can possibly live up to the last one.

During the August 6 episode of CNBC’s Mad Money, Jim Cramer pointed to a growing sector rotation as portfolio managers look for innovation outside the mega-cap technology space. He said: Finally, tech had such a run that portfolio managers want exposure to other sectors of the market that still have innovation. Think of them as […]

Four stocks built on investment-grade balance sheets and decades of payout discipline could quietly generate thousands in annual passive income without requiring you to touch a thing after you buy them.

The case for more upside rests on its obesity pill, and what changed is not the drug but who can now write it and who can now pay for it.

Reaching $13,000 a month in dividends sounds like a capital problem, but the real trap is choosing the wrong yield tier and watching income quietly erode while you sleep. Three buckets can get you there, each with a very different cost hiding beneath the headline number.

Amgen is back in focus after updated valuation work lifted its modeled fair value from US$352.23 to US$371.93 per share, signaling a higher price target in the latest analyst run. Much of Wall Street commentary around this shift ties to recent Q2 beats, raised guidance, and differing views on how durable the current growth and pipeline story really is. As you read on, you will see how these moving pieces shape the evolving Amgen narrative and what to watch next in the research. Stay updated...

The yield you chase at 52 could quietly cannibalize the very nest egg you need at 62. Before you reach for the biggest monthly payout, understand the compounding trap hiding inside each income tier.

A $1.25 million nest egg can fund a very different retirement depending on one number: your withdrawal yield. The gap between a conservative dividend portfolio and an aggressive one swings your annual income by tens of thousands of dollars, but the safer-looking choice does not always win.

If you hold shares, you're already exposed to a potential future where the stock is either far higher or far lower, and the options market is pricing both as real possibilities.

Replimune secures FDA approval for Tudriqev on its third attempt, making it the company’s first product on the market.

Ligand Pharmaceuticals (NASDAQ:LGND) reported second-quarter 2026 results marked by higher royalty revenue and adjusted earnings, while highlighting the post-quarter close of its XOMA Royalty acquisition and a $700 million zero-coupon convertible-note offering. Total revenue rose 34% year over year

Companies In The News Are: AMGN, ANET, WYNN< BKNG.

Rapid growth across cardiovascular, bone and rare-disease medicines allowed Amgen to raise guidance despite abandoning an obesity candidate.

Stocks were mostly higher again as Iran and Oman negotiated a shipping agreement for the Strait of Hormuz, but AI capex is still a big issue for investors.

Amgen Inc (NASDAQ:AMGN, XETRA:AMG) shares rose about 4% on Wednesday after the biotechnology company reported second quarter 2026 results that topped Wall Street expectations, supported by higher revenue and growth across its portfolio of medicines. The company reported adjusted earnings per...

Amgen beats Q2 earnings and revenue estimates and lifts its 2026 outlook. Key products witness strong growth despite biosimilar pressure on older drugs.

The S&P 500 Index ($SPX ) (SPY ) today is up +0.31%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +1.05%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.03%. September E-mini S&P futures (ESU26 ) are up +0.33%, and September E-mini Nasdaq futures...

The S&P 500 Index ($SPX ) (SPY ) today is up +0.46%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.74%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.51%. September E-mini S&P futures (ESU26 ) are up +0.50%, and September E-mini Nasdaq futures...

Amgen raised its 2026 outlook as broad product growth funds a deeper late-stage pipeline push amid biosimilar pressure on older franchises.

The biotech raised its full-year revenue forecast to $38.2 billion–$39.4 billion after second-quarter revenue rose 10% to $10.1 billion

Stock Market Today: The Dow Jones index rises Wednesday after surprise jobs data. AMD stock and SpaceX plunge on earnings.

8.30am: ADP jobs softens US private-sector hiring slowed to 44,000 jobs in July from 98,000 in June, missing the 65,000 forecast and pointing to cooling labour demand. The softer reading could give the Federal Reserve more scope to cut rates, weighing on Treasury yields and the dollar...

How Amgen’s latest earnings event sets the stage for investors Amgen (AMGN) just released its second quarter 2026 results, reporting revenue of US$10.05b and net income of US$2.38b, alongside updated full year guidance that gives investors fresh numbers to work with. For the first half of 2026, Amgen reported revenue of US$18.67b and net income of US$4.19b. Basic earnings per share from continuing operations were US$7.77, with diluted EPS at US$7.71 for the period. The company now expects...